LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

50.29 2.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

49.73

Massimo

50.7

Metriche Chiave

By Trading Economics

Entrata

-14M

-130M

Vendite

-888K

143K

Margine di Profitto

-90,972.727

Dipendenti

437

EBITDA

33K

-129M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+58.45% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

462M

4.5B

Apertura precedente

48.12

Chiusura precedente

50.29

Notizie sul Sentiment di mercato

By Acuity

56%

44%

294 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 dic 2025, 00:04 UTC

Acquisizioni, Fusioni, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

12 dic 2025, 16:42 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

13 dic 2025, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 08:00 UTC

Acquisizioni, Fusioni, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 07:00 UTC

Acquisizioni, Fusioni, Takeovers

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dic 2025, 00:24 UTC

Acquisizioni, Fusioni, Takeovers

Want a Piece Of SpaceX? -- Barrons.com

12 dic 2025, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Discorsi di Mercato

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Utili

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Utili

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Discorsi di Mercato

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Utili

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Discorsi di Mercato

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Utili

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12 dic 2025, 17:33 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12 dic 2025, 17:33 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12 dic 2025, 17:32 UTC

Acquisizioni, Fusioni, Takeovers

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12 dic 2025, 17:31 UTC

Acquisizioni, Fusioni, Takeovers

Orange to Buy the Stake for EU4.25B in Cash

12 dic 2025, 17:24 UTC

Discorsi di Mercato

Argentina Predicts Record Wheat Crop -- Market Talk

12 dic 2025, 17:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

12 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 dic 2025, 17:18 UTC

Discorsi di Mercato
Utili

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12 dic 2025, 17:09 UTC

Discorsi di Mercato

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12 dic 2025, 17:09 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

12 dic 2025, 16:47 UTC

Discorsi di Mercato

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

58.45% in crescita

Previsioni per 12 mesi

Media 80 USD  58.45%

Alto 108 USD

Basso 45 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

14

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

294 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat